
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/riedl-pharmaeconomics-2013-47 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:19:11 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Riedl Pharmaeconomics 2013 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Riedl Pharmaeconomics 2013"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/riedl-pharmaeconomics-2013-47"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/47/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Riedl Pharmaeconomics 2013"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/47/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="riedl-pharmaeconomics-2013-47.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/472679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Riedl Pharmaeconomics 2013</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1032</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="47">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="47">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/YPu"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Riedl%20Pharmaeconomics%202013&amp;url=https://hbs.hu/r/YPu"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/YPu&amp;title=Riedl%20Pharmaeconomics%202013&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/YPu"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="riedl-pharmaeconomics-2013-47.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/riedl-pharmaeconomics-2013-47"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/47?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="47" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>7. </p>
                                        
                                            <p>6. 15.  Clemens  JQ,  Markossian  T,  Calhoun  EA.  Comparison  of  eco- nomic impact of chronic prostatitis/chronic pelvic pain syndrome and   interstitial   cystitis/painful   bladder   syndrome.   Urology. 2009;73:743–6. 16.  Clemens JQ, Meenan RT, Rosetti MC, et al. Costs of interstitial cystitis in a managed care population. Urology. 2008;71:776–80. C. Riedl et al. </p>
                                        
                                            <p>5. US$4,300  per  patient  [ 10 ].  The  total  annual  costs  for  the diagnoses  ‘interstitial  cystitis’  and  ‘painful  bladder  syn- drome’ combined were about US$800 million in the year 2000,  with  a  constant  increase  throughout  the  preceding decade.  This  may  not  reflect  the  total  situation,  because only privately insured patients were analyzed. Anger  et  al.  calculated  total  annual  costs  of  US$2,808 per BPS/IC patient for the period 1999–2004 [ 13 ]. In their study, the majority of expenditure was attributable to oral medications,  while  instillations  were  used  in  fewer  than 25 % of patients. Wu  et  al.  found  that  the  average  BPS/IC  patient  had 130% higher direct medical costs than the average non-IC control individual [ 14 ]. Co-morbidities added significantly to the total costs of the disease. Those authors also stated that  following  diagnosis  of  BPS/IC,  patients  are  com- monly  untreated  or  are  treated  with  non-approved  drug therapies,  and  that  better  management  with  adequate  dis- ease-specific therapy might significantly reduce healthcare costs. Clemens  et  al.  [ 15 ]  investigated  patients  with  BPS/IC and  chronic  prostatitis  in  the  year  2005  and  calculated annual  direct  costs  of  US$3,631  and  US$3,017,  respec- tively, using Medicare rates, compared with US$7,043 and US$6,534, respectively, using non-Medicare rates. In another report by Clemens et al., the average annual costs   for   BPS/IC   were   found   to   be   approximately US$4,000 higher than those in age-matched controls [ 16 ]. Again, it is emphasized that these costs are underestimated, since  costs  preceding  the  diagnosis,  costs  of  alternative therapies and indirect costs are not included. In  the  present  study,  we  analyzed  the  annual  costs  of different    BPS/IC   therapies   that   are   compliant   with guideline  recommendations,  and  we  found  a  wide  range from € 2,526   to € 5,267,   depending   on   the   therapeutic regimen  that  was  used.  These  numbers  conform  well  to the data of the other researchers cited above. As would be expected, more effective therapies allowing the possibility of disease remission result in lower long-term costs. While the costs for the first year of therapy are quite similar for amitriptyline   and   intravesical   hyaluronan,   non-specific symptomatic  therapy  is  about  twice  as  expensive.  After 5 years,  the  costs  for  patients  treated  with  hyaluronan  are [ 40 %  less  compared  with  amitriptyline,  almost  60 % less  compared  with  pentosanpolysulfate  and  only  about  a third   of   the   costs   for   patients   receiving   non-specific symptomatic  therapy. 5  Conclusion The  findings  of  the  present  study  clearly  support  use  of therapies according to the current guidelines which, besides medical  efficacy,  also  results  in  the  most  cost-effective outcome.  In  addition,  it  is  essential  to  correctly  diagnose BPS/IC  as  early  as  possible,  since  use  of  non-specific symptomatic  therapies  is  the  most  expensive  treatment option.   Long-term   cost   effectiveness   is   crucial   in   the treatment of chronic diseases to limit expenses in individ- ual healthcare systems. Funding  and  conflict  of  interest  disclosure  statements Claus Riedl received no funding for performing this study and preparing this manuscript.  He has  acted  as an  expert consultant  and given  presen- tations for Bioniche Pharma. Paul  Engelhardt  has  no  potential  conflicts  of  interest  that  are directly relevant to the content of this manuscript. Bernhard Schwarz has received an honorarium for development of a disease-specific health economic model. References 1.  Hanno  P,  Dmochowski  R.  Status  of  international  consensus  on interstitial  cystitis/bladder  pain  syndrome:  2008  snapshot.  Neu- rourol Urodyn. 2009;28:274–86. 2.  Interstitial cystitis and painful bladder syndrome. In: Litwin MS, Saigal CS, editors. Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 2012, NIH Publication No. 12-7865. 3.  Temml  C,  Wehrberger  C,  Riedl  CR,  et  al.  Prevalence   and correlates    for    interstitial    cystitis    symptoms    in    women participating  in  a  health  screening  project.  Eur  Urol.  2006;51: 803–8. 4.  Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis  and  treatment  of  interstitial  cystitis/bladder  pain  syn- drome. J Urol. 2011;185:2162–70. 5.  Engelhardt PF, Morakis N, Daha LK, et al. Long-term results of intravesical  hyaluronan  therapy  in  bladder  pain  syndrome/inter- stitial cystitis (BPS/IC). Int Urogynecol J. 2011;22:401–5. 6.  Hwang  P,  Auclair  B,  Beechinor  D,  et  al.  Efficacy  of  pentosan polysulfate in the treatment of interstitial cystitis: a meta-analy- sis. Urology. 1997;50:39–43. 7.  van  Ophoven  A,  Hertle  L.  Long-term  results  of  amitriptyline treatment for interstitial cystitis. J Urol. 2005;174:1837–40. 8.  Riedl CR, Engelhardt PF, Daha LK, et al. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J. 2008;19:717–21. 9.  Hanno PM. Analysis of long-term elmiron therapy for interstitial cystitis. Urology. 1997;49 (Suppl 5A):93–9. 10.  Payne  CK,  Joyce  GF,  Wise  M,  et  al.  Interstitial  cystitis  and painful bladder syndrome. J Urol. 2007;177:2042–9. 11.  Richter Toft B, Nordling J. Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol. 2006;16:268–72. 12.  Kallestrup  EB,  Jorgensen  SS,  Nordling  J,  et  al.  Treatment  of interstitial  cystitis  with  Cystistat:  a  hyaluronic  acid  product. Scand J Urol Nephrol. 2005;39:143–7. 13.  Anger JT, Zabihi N, Clemens JQ, et al. Treatment choice, dura- tion,  and  cost  in  patients  with  interstitial  cystitis  and  painful bladder syndrome. Int Urogynecol J. 2011;22:395–400. 14.  Wu EQ, Birnbaum H, Mareva M, et al. Interstitial cystitis: cost, treatment  and  co-morbidities  in  an  employed  population.  Phar- macoeconomics. 2006;24:55–65. Treatment Costs of Bladder Pain Syndrome </p>
                                        
                                            <p>3. Data  on  costs  for  alternative  medicine  have  not  been published  but  were  estimated,  since  patients  who  receive no  therapeutic  benefit  from  standard  therapies  frequently seek aid outside evidence-based medicine; thus, this access is individual (Table 2 ). Medical office consultations were also calculated sepa- rately,  as  were  hospital  admissions  (in  patients  receiving only symptomatic therapy, they were reimbursed according to  International  Statistical  Classification  of  Diseases  and Related  Health  Problems [ICD]-10 code  N30.1). The rate of  inpatient  care  for  symptomatic  BPS/IC  patients  was calculated as 0.8/100,000 [ 10 ]. Patients  receiving  only  symptomatic  therapy  tend  to receive a greater number of medical and additional thera- pies  to  achieve  symptom  relief;  thus,  the  costs  of  their medical and other therapies were doubled (Table 2 ). Finally, a mean of 14 days of work loss was added for each patient without symptom remission. Published data on ambulatory   surgery   in   BPS/IC   patients   suggest   that 12–16 days of work are lost per patient per year [ 10 ]. Each day of work loss was costed at € 154, according to Austrian statistics.  The  costs  of  work  loss  were  included  in  the additional costs of disease in Table 2 . In  conclusion,  all  disease-related  costs  were  summa- rized  for  periods  of  1,  5  and  10 years  for  each  treatment group. 3  Results For  calculation  of  medication  costs  in  the  first  year,  the costs per unit were multiplied by the numbers of units used. For total treatment costs, the costs of additional  therapies were  added  (Table 3 ).  For  this,  the  additional  treatment costs from Table 2 were adjusted for the remission rates of the   individual   therapies,   i.e.   total   additional   treatment costs 9 (1 - remission  rate).  Since  a  relevant  proportion of  non-responders  would  need  more  additional  therapies for  symptom  relief,  a  correction  factor  was  introduced: 50 % of non-responders were assigned to the full range of symptomatic  therapy,  and  this  number  was  added  to  the first year’s total costs (Fig. 1 ). Disease-specific drug therapy Symptomatic therapy Remission No further therapy Response No response Continued disease- specific drug therapy and/or additional therapies Intensified additional  therapies 50% 50% Fig. 1 Algorithm for treatment of bladder pain syndrome/ interstitial cystitis (BPS/IC), depending on the response to disease-specific or symptomatic therapy Table 2 Annual costs (expressed in 2012 values) of additional therapies received by non-responders to therapies for bladder pain syndrome/ interstitial cystitis (BPS/IC) in Austria Additional therapies Costs ( € ) Per unit Non- responders to hyaluronan Non-responders to pentosanpolysulfate Non-responders to amitriptyline Non-responders to symptomatic therapy Physician visit                    40        160                     160                               160                         320 Hospitalization              1,250            0                         0                                   0                      1,875 Drug therapy                    150        150                     150                               150                         300 Complementary medicine 200        200                     200                               200                         400 Physiotherapy                  108        108                     108                               108                         216 Work loss (14 days)        154     2,156                  2,156                            2,156                      2,156 Total                                            2,774                  2,774                            2,774                      5,267 Treatment Costs of Bladder Pain Syndrome </p>
                                        
                                            <p>2. € 2,000,000  per  100,000  persons  for  BPS/IC  therapy.  For a  country  such  as  Austria,  with  8,000,000  inhabitants, this   would   mean   total   annual   costs   of   approximately US$200,000,000/ € 160,000,000. A variety of therapies have been suggested for BPS/IC and  were  recently  evaluated  by  the  American  Urologic Association  (AUA)  and  included  in  treatment  guidelines [ 4 ].  These  treatments  include  behavioural  recommenda- tions,  oral  medications,  bladder  instillations  and  invasive therapies/operations.  The  costs  of  these  therapies  vary widely and have not been compared before. In particular, the  possibility  of  a  cure  has  not  been  taken  into  account, which  could  significantly  reduce  patient  morbidity  and treatment costs. Reports  on  instillation  therapy  with  hyaluronan  have shown long-term symptom remission at [ 5 years in about 50 % of BPS/IC patients, suggesting that a cure is possible for at least some of them [ 5 ]. We analyzed treatment costs in Austria, a country with a public health system with open access  for  the  wide  majority  of  inhabitants,  under  the special assumption that hyaluronan therapy has the poten- tial to cure BPS/IC patients. 2  Methods The  annual  costs  of  medical  BPS/IC  therapies  recom- mended by the AUA guidelines were calculated. The fol- lowing therapies were compared: oral pentosanpolysulfate (300 mg  daily);  amitriptyline  (25 mg  daily);  hyaluronan instillations  (12  instillations);  and  symptomatic  therapy (which applies to all individuals with a delayed diagnosis of BPS/IC and, thus, administration of inappropriate ther- apies). The dosages/frequencies of applications were cho- sen with respect to published data and represent the most commonly used units [ 6 – 8 ]. In the next step, treatment costs for Austria were eval- uated   and   are   presented   in   Table 1 .   For   symptomatic therapy,   the   most   inexpensive   drugs   were   used   for calculation,  presenting  the  minimal  cost  range.  Normally, patients with chronic unresponsive diseases tend to receive more  expensive,  non-standard  medications,  which  would result in significantly higher total costs for this symptom- atically treated group. Symptom  remission  rates  were  taken  from  published data and constituted the basis for evaluation of the costs of additional therapies in the first and subsequent years. It was presumed that all patients who did not experience complete resolution of symptoms would receive additional therapies. The   algorithm   for   treatment   of   responders   and   non- responders  is  shown  in  Fig. 1 .  Symptom  remission  was reported in 70 % of patients  in the  hyaluronan group  [ 8 ], including  20 %  of  patients  needing  monthly  maintenance therapy  over  a  period  of  years.  No  complete  symptom remission, but symptom reduction as a treatment response, was  reported  in  approximately  60 %  of  pentosanpoly- sulfate-treated  patients  [ 9 ]  and  in  65 %  of  amitriptyline- treated  patients  [ 7 ].  Because  symptom  reduction  reduces the necessity for additional treatments, this was calculated as a 50 % remission (‘ratio of effectiveness response versus remission’). For the pentosanpolysulfate and amitriptyline groups,   remission   rates   of   30 %   (based   on   the   60 % response  rate  reported  above)  and  32.5 %  (based  on  the 65 %  response  rate  reported  above),  respectively,  were assumed. No remission would be expected in symptomat- ically treated patients. Additional  therapies,  which  reduce  pain  and  bladder symptoms   in   symptomatic   patients   un-responsive   to   a specific therapy and are the primary therapy in symptom- atically  treated  patients,  include  analgesics,  anticholiner- gics,  antibiotics,  sedatives  (Table 1 )  and  physiotherapy (for  a  wide  range  of  various  therapies,  from  pelvic  floor relaxation to lower back treatments, an average of 3 hours per  patient  per  year  was  assumed,  since  not  all  patients would receive physiotherapy). The costs of these therapies were  calculated for  the  Austrian  health  system, and  these costs were added to the individual treatment groups for all non-responders (Table 2 ). Table 1 Costs  (expressed  in  2012  values)  of  guideline-recommended  therapies  for  bladder  pain  syndrome/interstitial  cystitis  (BPS/IC)  in Austria Basic parameters for cost calculations                                           Costs ( € ) Hyaluronan       Pentosanpolysulfate       Amitriptyline       Symptomatic therapy Cost per unit                                                                                   110                    100                                 7.25 No. of units in the first year (responders ? non-responders)       12                      12                                   12 No. of units in subsequent years (non-responders only)               3.6                     8.4                                  8.1 Medication cost in the first year                                                    1,320                 1,200                              87                         150 a Cost per follow-up year                                                                  264                    840                                 59                         150 a a Analgesics (extended-release diclofenac 75 mg twice daily) € 89; antibiotics (trimethoprim 200 mg 4 times/year) € 7; anticholinergics (trospium chloride 20 mg twice daily) € 41; sedatives (alprazolam 0.5 mg once daily) € 13 C. Riedl et al. </p>
                                        
                                            <p>8. © 2013 Springer International Publishing Switzerland “Treatment  Costs  of  Bladder  Pain  Syndrome/Interstitial  Cystitis  in  Austria:  A  Pharmacoeconomic  Approach  Following  Current  Guidelines”, Claus Riedl et al.  Clinical Drug Investigation  2013; DOI 10.1007/s40261-013-0119-4. This article reprint is a published-ahead-of-print version and may be subject to changes in the final published article. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic,  including photocopying, recording, or through an information storage and retrieval system, without the previous written permission of  Springer Healthcare. Although great care has been taken in compiling and verifying the information contained in this publication, Springer Healthcare and  its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for  any  consequences  arising  therefrom.  Neither  are  they  responsible  for  any  possible  damages  caused  to  individuals  or  institutions  which may arise from the use of the information, methods, products, instructions and ideas expressed in this publication. Given the  rapid  progression  with  which  medical  sciences  move  forward,  Springer  Healthcare  and  its  servants  recommend  that  the  latest  dosage and diagnosis are checked at all times aside from those given in this publication. Inclusion or exclusion of any product does  not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement.  The opinions expressed do not necessarily reflect the views of Springer Healthcare and its servants. Springer SBM Spain, S.A.U. Orense, 16 - 2° (Oficinas). 28020 Madrid. Spain Tel.: +34 91 555 40 62. Fax: +34 91 555 76 89 E-mail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="135966727d3d77767f725566767d6776536063617a7d7476613d707c7e">[email&#160;protected]</a> www.springerhealthcare.com www.formacionspringerhealthcare.com A Quality System Certified ISO-9001 Company   Depósito Legal: M-18944-2012 </p>
                                        
                                            <p>1. ORIGINAL RESEARCH ARTICLE Treatment Costs of Bladder Pain Syndrome/Interstitial Cystitis in Austria: A Pharmacoeconomic Approach Following Current Guidelines Claus Riedl • Paul Engelhardt • Bernhard Schwarz Ó Springer International Publishing Switzerland 2013 Abstract Background Bladder   pain   syndrome/interstitial   cystitis (BPS/IC) is a chronic disease with a significant impact on quality of life. A broad range of therapies are used to treat this   condition,   and   patients   are   often   excluded   from receiving  more  expensive  and  more  effective  therapies because of cost issues. Objective The  objective  of  this  study  was  to  assess  the mid- and long-term costs (over 1, 5 and 10 years) of var- ious therapies for BPS/IC. Methods Costs in an open-access health system (Austria) for  three  BPS/IC-specific  therapies  (intravesical  hyaluro- nan, pentosanpolysulfate and amitriptyline), taken from the American  Urological  Association  guidelines,  were  evalu- ated and compared with those of non-specific symptomatic therapies.  Response  rates  for  the  different  therapies  were taken from peer-reviewed publications and used  to define the need for therapy maintenance with regard to symptom improvement. Results Despite the highest initial costs, the reduced need for  further  therapy  in  patients  with  long-term  symptom remission  after  hyaluronan  therapy  resulted  in  the  lowest total  treatment  costs  at  all  three  timepoints.  Hyaluronan was   cost   saving   against   all   alternatives   in   standard assumptions and in all sensitivity analyses. As a limitation, treatment  costs   in  this   study   are   specific  for   Austria. However,  the  template  used  for  calculation  of  treatment costs can be transferred to all countries by inserting local prices. Conclusion Disease-specific  therapies  with  high  remis- sion  rates  result  in  significantly  lower  long-term  costs  in BPS/IC.   Non-specific   symptomatic   therapies   are   most expensive.  Long-term  cost  effectiveness  is  crucial  in  the treatment of chronic diseases to limit expenses in individ- ual healthcare systems. 1  Introduction Chronic diseases present an increasing burden to healthcare systems. Continuous improvement in medicine has reduced the  number  of  fatalities  from  severe  diseases  but  has increased  the  number  of  patients  suffering  from  chronic illness.  Many  of  these  patients  need  permanent  medical care,  which  has  an  enormous  impact  on  total  medical lifetime costs. Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, which significantly affects patients lives. It is  characterized  by  pain  related  to  the  urinary  bladder, accompanied by at least one other urinary symptom such as day-time  and  night-time  frequency  [ 1 ].  Quality  of  life  in patients  with  BPS/IC  has  been  rated  lower  than  that  of patients  on  chronic  haemodialysis  or  with  other  chronic diseases. Since BPS/IC may start in early adulthood and is not  life  threatening,  the  course  of  disease  may  run  for several decades and, thus, treatment costs may reach con- siderable  values.  In  a  study  by  the  Urologic  Diseases  in America Project, the average annual total medical costs per BPS/IC patient were US$7,597 in 2004 and US$17,407 in 2012 [ 2 ]. With minimum annual costs of around US$8,000 per  patient  and  a  BPS/IC  prevalence  of  300/100,000  [ 3 ], this   results   in   annual   costs   of   about   US$2,500,000/ C. Riedl ( &amp; )  P. Engelhardt Department of Urology, Landesklinikum Baden-Mo  ̈ dling, Wimmergasse 19, 2500 Baden, Austria e-mail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="50333c3125237e223935343c10323134353e7e3c3b3e3f357e3124">[email&#160;protected]</a>; <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="cdbfa4a8a9a1ae8daea2a0bdb8bea8bfbba8e3aea2a0">[email&#160;protected]</a> B. Schwarz Karl Landsteiner Institute for Health Economics, Center for Public Health, Medical University Vienna, Vienna, Austria Clin Drug Investig DOI 10.1007/s40261-013-0119-4 </p>
                                        
                                            <p>4. In  summary,  after  the  first  year  of  therapy,  the  costs were € 2,526  for  patients  in  the  hyaluronan  group, € 4,014 for those in the pentosanpolysulfate group, € 2,801 for those in   the   amitriptyline   group   and € 5,267   for   the   group receiving only symptomatic therapy. To  calculate  5-year  costs,  the  annual  costs  of  disease- specific  therapy  were  added  to  the  first-year  costs,  and again the annual costs of additional therapies (50 % normal costs, 50 % increased costs of full-range therapy) for non- responders  were  added.  This  resulted  in  5-year  costs  of € 8,407  for  hyaluronan, € 18,632  for  pentosanpolysulfate, € 13,891  for  amitriptyline  and € 26,335  for  symptomatic therapy. This strategy was also used for 10-year cost calculations, since  no  late  disease  remissions  with  or  without  specific therapy  have  been  reported  for  BPS/IC.  The  costs  after 10 years   were € 15,758   for   hyaluronan, € 36,904   for pentosanpolysulfate, € 27,754 for amitriptyline and € 52,670 for symptomatic therapy. Hyaluronan was cost saving against all alternatives. The incremental  costs  of  hyaluronan  versus  the  alternatives were - € 10.225  versus  pentosanpolysulfate, - € 5.484  ver- sus   amitriptyline   and - € 17.928   versus   symptomatic therapy. In one-way sensitivity analyses, the duration of follow- up was a key driver of cost differences between hyaluronan and  the  alternatives.  Variations  in  other  parameters  (the response/remission   rates,   costs   of   additional   therapy, hospital admissions) had lesser effects on incremental costs (Table 4 ). 4  Discussion The  present  results  emphasize  the  fact  that  BPS/IC  is  an expensive disease if the opportunity for a correct and early diagnosis  is  missed  and  no  disease-specific  and  effective therapies  are   initiated.   For  a   long   time,   palliation   by endoscopic  procedures,  surgical  procedures,  intravesical medical  therapies  or  systemic  medical  therapies  has  been the only way to alleviate patients’ symptoms. Intravesical glycosaminoglycan (GAG)-substitution therapy has gained increasing   awareness   throughout   the   last   two   decades because of its high rate of symptomatic relief [ 11 ]. A  first  report  by  Kallestrup  et  al.  [ 12 ]  on  long-term symptom  remission  with  intravesical  hyaluronan  therapy was confirmed by Engelhardt et al. [ 5 ], suggesting that about 50 % of patients remain symptom free after initial instilla- tion therapy, and another 20 % remain symptom free with monthly maintenance instillations. The potential to cure this chronic disease was first spotlighted by these authors. Con- sidering the relatively high costs of hyaluronan instillation therapy,  this  adds  new  perspectives  to  the  situation  of BPS/IC patients and the costs of this chronic disease. Payne  et  al.  estimated  that  the  USA’s  annual  expendi- ture   for   BPS/IC   in   the   period   1994–2000   was   about Table 3 Total costs (expressed in 2012 values) for bladder pain syndrome/interstitial cystitis (BPS/IC) therapy in Austria Hyaluronan         Pentosanpolysulfate         Amitriptyline         Symptomatic therapy Medication costs during the first year ( € )                               1,320                   1,200                                      87                         300 Remission rate calculated from the response rate (%)                70                        30                                      32.5                          0 Additional costs per year for non-responders ( € )                       832                   1,942                                 1,872                      5,267 Total costs during the first year ( € )                                         2,526                   4,014                                 2,801                      5,267 5-year costs ( € )                                                                         8,407                 18,632                               13,891                    26,335 10-year costs ( € )                                                                     15,758                 36,904                               27,754                    52,670 Table 4 Incremental costs (expressed in 2012 values) of hyaluronan vs alternative therapies: standard assumptions and one-way sensitivity analysis Costs ( € ) Vs pentosanpolysulfate Vs amitriptyline Vs symptomatic therapy Standard assumptions, 5-year follow-up - 10,225 - 5,484 - 17,928 1-year follow-up - 1,488 - 275 - 2,741 10-year follow-up - 21,146 - 11,996 - 36,913 Ratio of effectiveness response vs remission 30 % - 13,213 - 8,143 - 17,928 Ratio of effectiveness response vs remission 70 % - 7,237 - 2,826 - 17,928 Costs of symptomatic drug therapy ? 100 % - 10,675 - 5,906 - 19,091 No. of hospital admissions 0.75/year - 9,288 - 4,605 - 13,944 No. of hospital admissions 3.0/year - 12,100 - 7,242 - 25,897 C. Riedl et al. </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="riedl-pharmaeconomics-2013-47.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1032</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">760</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">272</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">4</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">5</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1473 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1385 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1464 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1304 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1362 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1414 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1368 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1489 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1221 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1388 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1251 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1389 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1311 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1301 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1359 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1774 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1709 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1620 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="234a4d454c634b41500d4b56">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/riedl-pharmaeconomics-2013-47 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:19:15 GMT -->
</html>
    
    
